Status:
UNKNOWN
The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Healthy Volunteers
Eligibility:
All Genders
19-55 years
Phase:
PHASE1
Brief Summary
This study aims to evaluate the pharmacokinetic and pharmacodynamic characteristics and safety of co-administration of DWP16001 2 mg and DWC202010 (DWC202010 37.5 mg) in healthy adults compared to the...
Detailed Description
The study design is a randomized, open-label, multiple-dose, crossover clinical trial. The patients were randomly assigned to each group. Primary endpoint was Cmax,ss and AUCtau,ss of DWP16001 and DWC...
Eligibility Criteria
Inclusion
- \-
Exclusion
- \-
Key Trial Info
Start Date :
December 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT05321732
Start Date
December 10 2021
End Date
August 1 2022
Last Update
April 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University Severance Hospital
Seoul, South Korea